ADMA Biologics Inc vs Snowflake Inc — how do they compare? ADMA Biologics Inc trades at $9.88 (market cap $2.22B), while Snowflake Inc trades at $331.5 (market cap $116.01B). The key difference: Snowflake Inc is far larger — about 52.3× ADMA Biologics Inc's market cap, and Snowflake Inc is trading nearer its 52-week high, ADMA Biologics Inc nearer its low. Which is the better fit depends on your goals.
| ADMA | SNOW | |
|---|---|---|
Market Cap | $2.22B | $116.01B |
Sector | Health | Technology |
52-Week High | $20.38 | $334.70 |
52-Week Low | $7.60 | $121.11 |
Enterprise Value | $2.29B | $115.82B |
Signals from Pluang's Aura AI — not financial advice
ADMA trades at $9.78, up 0.31% today, with a bullish technical signal from moving averages and strong fundamentals including a 32.98% net income margin and 41.9% ROE. Recent earnings show a mix of beats and misses, with Q3 2026 EPS expected at $0.19. The stock faces headwinds from multiple class-action lawsuits alleging securities fraud, as reported by news outlets in August 2026.
Outlook is cautiously optimistic due to robust profitability and analyst support, but legal risks and recent earnings volatility pose challenges. Investment opportunity hinges on legal resolution and sustained earnings growth, with risks including litigation outcomes and competitive pressures in the biologics sector.
Snowflake (SNOW) trades at $334.30, down 0.12% on the day, with a bullish technical signal from moving averages but overbought RSI readings. The company reported strong revenue growth to $3.63 billion in 2025, though net losses persist at -$1.29 billion. Recent news highlights AI platform enhancements and investor conferences, with earnings beats in the last three quarters.
Outlook remains growth-focused with AI adoption driving upside, but premium valuation (P/S 22.66) and sustained losses pose risks. Analyst consensus is bullish with an 80.77% buy rating, though competition and margin pressure require monitoring for stock investors.
Trailing returns across standard periods
Latest headlines on both assets
ADMA Biologics is a biopharmaceutical company specializing in plasma-derived therapies for immunodeficient patients. Key products like ASCENIV and BIVIGAM treat primary humoral immunodeficiency and help prevent infectious diseases.
Read more on ADMA →Founded in 2012, Snowflake is a data lake, warehousing, and sharing company that came public in 2020. To date, the company has over 3,000 customers including nearly 30% of the Fortune 500 as its customers. Snowflake's data lake stores unstructured and semistructured data that can then be used in analytics to create insights stored in its data warehouse. Snowflake's data sharing capability allows enterprises to easily buy and ingest data almost instantaneously compared with a traditionally months-long process. Overall, the company is known for the fact that all of its data solutions that can be hosted on various public clouds.
Read more on SNOW →